Insulin Market in the US and Europe 2016-2020: New research report available at Fast Market Research

Beta cells of the pancreas produce insulin, a hormone that regulates blood glucose levels, by stimulating cells to absorb glucose from the blood. In the cells, glucose is converted into energy, which is used by tissues and muscles to perform their physiological functions. This process is restricted in people with diabetes, resulting in the accumulation of glucose in the blood. This condition is known as hyperglycemia; it damages body tissues over a period, leading to life-threatening health complications such as diabetic retinopathy and diabetic nephropathy. In type 1 diabetes or gestational diabetes, the immune system attacks the pancreatic cells, resulting in little or no insulin production. In type 2 diabetes, the body does not produce sufficient insulin to regulate blood glucose levels. In both type 1 and type 2 diabetes, the individual requires daily doses of insulin along with other medications, depending on the condition. Different types of insulin products, such as human insulin and insulin analogs, are available for insulin replacement therapy.

Full Report Details at
- http://www.fastmr.com/prod/1171594_insulin_us_europe_20162020.aspx?afid=301

Technavio's analysts forecast the insulin market in the US and Europe to grow at a CAGR of 6.17% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the insulin market in the US and Europe for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the branded drugs during the forecast period.

The market is divided into the following segments based on geography:

* US
* Europe

Technavio's report, Insulin Market in the US and Europe 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

* Sanofi
* Novo Nordisk
* Eli Lilly

Other prominent vendors

* Adocia
* Biocon
* Biodel
* Biogenomics
* Boehringer Ingelheim
* Dance Biopharm
* Diasome Pharmaceuticals
* Exsulin
* Generex
* Lexicon Pharmaceuticals
* Ligand Pharmaceuticals
* MannKind
* Macrogenics
* Merck
* Melior Pharmaceuticals
* Metabolic Solutions Development Company
* NGM Biopharmaceuticals
* NuSirt Biopharma
* Oramed Pharmceuticals
* PhaseBio Pharmaceuticals
* Pfizer
* Thermalin Diabetes
* Tolerion
* VeroScience
* vTv Therapeutics
* Wockhardt
* XOMA

Market driver

* Advances in insulin delivery technology
* For a full, detailed list, view our report

Market challenge

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Insulin Market in Europe 2015-2019
- Insulin Markets in Europe to 2019 - Market Size, Development, and Forecasts
- Insulin Markets in Western Europe to 2019 - Market Size, Development, and Forecasts
- Insulin Markets in Eastern Europe to 2019 - Market Size, Development, and Forecasts
- Human Insulin Market - Forecasts to 2020